|
| |
Current Clinical Trials
Angina |
| Therapeutic Area: |
Angina |
| Principal Investigator: |
Dr. Michael Azrin |
| Title: |
Protocol #TMC-BIV-02-08, version date 12 May
2003: The Acuity Trial: A Randomized Comparison of Angiomax® (bivalirudin)
Versus Lovenox®/Clexane® (enoxaparin) in Patients Undergoing
Early Invasive Management for Acute Coronary Syndromes without
ST-segment Elevation |
| Description: |
In patients with angina, or chest pain
from blockages in the blood vessels supplying the heart, an
angiogram is recommended. During an angiogram, blood thinning
medication, such as enoxaparin and bivalirudin are used. The
ACUITY Trial is a randomized comparison between bivalirudin and
enoxaparin in patients with acute coronary syndrome who will be
having an angiogram. |
| Length/Duration: |
1 year |
| Compensation: |
None |
| Location: |
UConn Health Center |
| Contact: |
Cheryl Martin, R.N., at 860-679-2943 |
| IRB#: |
04-176 |
[back to top]
Atrial Fibrillation |
| Therapeutic Area: |
Atrial Fibrillation |
| Principal Investigator: |
Dr. Bruce T. Liang |
| Description: |
Atrial fibrillation is an abnormal heart
rhythm in which the heart beats irregularly, due to disorganized
electrical activity in the atria (upper chambers of the heart).
This results in irregular and rapid beating of the ventricles
(lower chambers of the heart). The condition occurs in up to 40
percent of patients following heart surgery. We are trying to
learn what happens to heart cells in the atria during heart
surgery that causes or prolongs atrial fibrillation, and are
inviting patients undergoing open heart surgery to participate
in this study. |
| Length/Duration: |
1 visit. Study is open only to patients scheduled
for open heart surgery at John Dempsey
Hospital |
| Compensation: |
None |
| Location: |
UConn Health Center |
| Contact: |
Jill DesJardins, A.P.R.N., at
860-679-3252 |
| IRB#: |
02-200 |
[back to top]
Cardiology |
| Therapeutic Area: |
Cardiology |
| Principal Investigator: |
Dr. Michael Azrin |
| Title: |
Event Registry |
| Description: |
A new era for intervention cardiology has
begun with the introduction of drug eluting stents (DES).
Clinical trials indicate that these stents are considerably
superior to the current generation of bare metal stents (BMS)
with regard to in-stent restenosis and the need for target
vessel revascularization. The purpose of this study is to
collect data to determine if an increased use of drug eluting
stents is associated with an increase in after procedure
complication such as in-stent restenosis. This registry seeks to
compare the use of drug-eluting stents with the use of bare
metal stents according to age, gender, health status and type of
blockage. |
| Length/Duration: |
1 year |
| Compensation: |
None |
| Location: |
UConn Health Center |
| Contact: |
Cheryl Martin, R.N., at 860-679-2943 |
| IRB#: |
05-020 |
[back to top]
Cerebrovascular Diseases |
| Therapeutic Area: |
Cerebrovascular Diseases |
| Principal Investigator: |
Drs.
Leslie Wolfson and
William White |
| Title: |
White Matter Brain Disease and Vascular Risk |
| Description: |
Study for men and women 70 years and older with
limited mobility or problems with gait. Patients will undergo 2 weeks of tests including neurological exam, special assessment of gait and balance, magnetic resonance image of the brain, 24 hour
blood pressure monitoring and laboratory tests. All are free of charge. Sponsor: National Institutes of Health. |
| Length/Duration: |
Up to 4 years |
| Compensation: |
Transportation arranged and compensation provided
to get to all visits. |
| Location: |
UConn Health Center and the Institute of Living |
| Contact: |
Julia Schmidt, Project Manager, at 860-679-2705 |
| IRB#: |
03-129H |
[back to top]
Congestive Heart Failure |
| Therapeutic Area: |
Congestive Heart Failure |
| Principal Investigator: |
Dr. David Hager |
| Title: |
Protocol #A034, version date 17 March 2004:
Follow-Up Serial Infusions of Natrecor® (Nesiritide) for the
Management of Patients with Heart Failure – FUSION II |
| Description: |
FUSION II is a clinical research project
aimed at improving the quality of life and decreasing the
frequency of hospitalizations for patients with congestive heart
failure. The study evaluates patients with congestive heart
failure and involves administering weekly infusions of a
medication which both helps the kidneys excrete excess water and
also lowers pressures in the lungs so that breathing is more
comfortable. Patients will be evaluated, treated, and cared for
by a team of doctors and nurses experienced in treating heart
failure over the course of the study which lasts 24 weeks. |
| Length/Duration: |
24 weeks |
| Compensation: |
None |
| Location: |
UConn Health Center |
| Contact: |
Marybeth Barry, A.P.R.N., at
860-679-4121 |
| IRB#: |
04-249 |
Congestive Heart Failure |
| Therapeutic Area: |
Congestive Heart Failure |
| Principal Investigator: |
Dr. Bruce T. Liang |
| Title: |
Novel Circulating Marker to Detect Heart Failure |
| Description: |
This clinical scientific study looks at
potentially new factor or protein in blood to detect onset of heart failure. The detection of such circulating factor may even predict adverse outcome in the future. |
| Length/Duration: |
8 weeks |
| Compensation: |
None |
| Location: |
UConn Health Center |
| Contact: |
Jayne Schumacher, R.N., at 860-679-2692 |
| IRB#: |
06-1512 |
[back to top]
Coronary Artery Disease |
| Therapeutic Area: |
Coronary Artery Disease |
| Principal Investigator: |
Dr. Bruce T. Liang |
| Title: |
Circulating Adenosine Levels Before and After
IV Persantine |
| Description: |
The objective here is to determine how
well the drug stress test works for patients suspected of having
coronary artery disease, the most common form of heart disease.
The study involves taking a small amount of blood before and
after giving the drug, persantine, and determining the response
through testing. |
| Length/Duration: |
2 years |
| Compensation: |
None |
| Location: |
UConn Health Center/VA Medical Center |
| Contact: |
Dr. William Hiser at 860-679-3343 |
| IRB#: |
02-115 |
Coronary Artery Disease |
| Therapeutic Area: |
Coronary Artery Disease |
| Principal Investigator: |
Dr. Bruce T. Liang |
| Title: |
Novel Circulating Marker to Detect Coronary
Artery Disease and Ischemia |
| Description: |
This clinical scientific study looks at
potentially new factor or protein in blood to detect even very small damage in the heart muscle as a result of coronary artery hardening. The detection of such circulating factor may even predict
adverse outcome in the future. |
| Length/Duration: |
8 weeks |
| Compensation: |
None |
| Location: |
UConn Health Center |
| Contact: |
Jayne Schumacher, R.N., at 860-679-2692 |
| IRB#: |
07-2522 |
[back to top]
Dyspnea |
| Therapeutic Area: |
Dyspnea |
| Principal Investigator: |
Dr. Nausherwan K. Burki |
| Title: |
Airway Sensory Nerves and Dyspnea in Human
Subjects |
| Description: |
We are undertaking a research study
evaluating the sensation of breathlessness. Subjects should be
either healthy non-smokers with no heart, lung or other disease
or abnormality, and between the ages of 18 and 50 years, or
stable asthmatics, with no heart, or other disease or
abnormality, and between the ages of 18 and 50 years. |
| Length/Duration: |
14 months |
| Compensation: |
$30 per experimental day |
| Location: |
UConn Health Center |
| Contact: |
Dr. Nausherwan K. Burki at
860-679-3585 |
| IRB#: |
04-099 |
[back to top]
Heart and Vascular Diseases |
| Therapeutic Area: |
Heart and Vascular Diseases |
| Principal Investigator: |
Dr. Bruce T. Liang |
| Title: |
Regulation of Adenosine A1 Receptor in Atria of
Patients with Heart Failure |
| Description: |
The objective here is to study changes in
a number of factors that are important in regulating blood flow
and platelet function. Cellular changes for the proteins and
genes are measured. The study may ultimately demonstrate new way
to treat heart and vascular diseases. |
| Length/Duration: |
2 years |
| Compensation: |
None |
| Location: |
UConn Health Center/VA Medical Center |
| Contact: |
Drs. Bruce Liang and Michael Dahn at
860-679-3343 |
| IRB#: |
02-117 |
[back to top]
Heart Attack |
| Therapeutic Area: |
Heart Attack |
| Principal Investigator: |
Dr. Michael Azrin |
| Title: |
Time to Integrilin Therapy in Acute Myocardial
InfarctioN (TITAN) – TIMI 34 Trial |
| Description: |
Intravenous inhibitors of platelet function are
often administered to patients experiencing a heart attack. The TITAN study is being performed to define the optimal timing of administration of one of these frequently used drugs. In patients who
are experiencing a heart attack, the drug Integrelin will either be administered in the emergency room or will be administered at the time of an angioplasty to determine the optimal timing of
administration. |
| Length/Duration: |
Hospital stay plus phone call |
| Compensation: |
None |
| Location: |
UConn Health Center |
| Contact: |
Cheryl Martin, R.N., at 860-679-2943 |
| IRB#: |
04-266 |
Heart Attack |
| Therapeutic Area: |
Heart Attack |
| Principal Investigator: |
Dr. Michael Azrin |
| Title: |
APEX AMI Trial (Assessment of Pexelizumab in
Acute Myocardial Infarction) |
| Description: |
More than 1,000,000 patients worldwide
survive a heart attack each year. The COMMA study undertaken
recently at the UConn Health Center showed a significant
reduction in deaths 90 days after a heart attack when the
experimental drug Pexelizumab was used along with the usual
treatment for a heart attack. In order to obtain additional
information about how patients respond to the experimental drug,
Pexelizumab, the APEX AMI study will enroll acute heart attack
patients who will be randomly assigned to receive the usual
heart attack treatment prescribed by their doctor (50 percent of
patients), or Pexelizumab plus the usual treatment (remaining 50
percent of patients). Pexelizumab will be administered for only
24 hours. |
| Length/Duration: |
1 year |
| Compensation: |
None |
| Location: |
UConn Health Center |
| Contact: |
Cheryl Martin, R.N., at 860-679-2943 |
| IRB#: |
05-070 |
[back to top]
High Blood Pressure (Hypertension) |
| Therapeutic Area: |
Hypertension |
| Principal Investigator: |
Dr. William White |
| Title: |
Angiotensin Receptor Blockers in Hypertension |
| Description: |
Study for men and women, 21 years or older, with
essential hypertension; this study will evaluate different doses of an investigational medication for hypertension called TAK-491 , an angiotensin blocker (Takeda Pharmaceuticals); all visits,
tests, and medications are supplied free of charge. |
| Length/Duration: |
14 weeks |
| Compensation: |
Up to $240 |
| Location: |
UConn Health Center |
| Contact: |
Sharon Giacco, R.N., C.C.R.P., at
860-679-4116 |
| IRB#: |
07-275-1 |
[back to top]
Mitral Valve
Prolapse |
| Therapeutic Area: |
Mitral Valve
Prolapse |
| Principal Investigator: |
Dr. Erick Avelar |
| Title: |
Have You Been Diagnosed with Mitral Valve Prolapse? |
| Description: |
Would you like to help find a reason for this common problem? Consider
participating in our Mitral Valve Prolapse genetic research study at the
University of Connecticut Health Center. We are conducting this research in
collaboration with the Massachusetts General Hospital at Harvard University
School of Medicine. |
| Length/Duration: |
Participation in this study involves a one-time blood draw and a brief
interview about your family history. This will not take more than one hour
of your time. |
| Compensation: |
None |
| Location: |
UConn Health Center |
| Contact: |
David Inyangetor, M.D., Research Coordinator, at 803-463-6797 |
| IRB#: |
09-099-2 |
[back to top]
Type 2 Diabetes |
| Therapeutic Area: |
Type 2 Diabetes |
| Principal Investigator: |
Dr. Michael Azrin |
| Title: |
Protocol # 01-01-TL-OPI-516 version date 30
April 2004: A Double-Blind, Randomized, Comparator-Controlled
Study in Subjects with Type 2 Diabetes Mellitus Comparing the
Effects of Pioglitazone HCL versus Glimepirade on the Rate of
Progression of Coronary Atherosclerotic Disease as Measured by
Intravascular Ultrasound |
| Description: |
Patients with Type 2 diabetes have a high
risk of developing many serious complications, including
cardiovascular events such as heart attack, amputations and
stroke. Clinical studies have demonstrated that the class of
diabetic drugs known as Thiazolidinediones (TZD's) improve
several risk factors for cardiovascular events and also have
other actions that may prove beneficial to decreasing the build
up of blockages in blood vessels. |
| Length/Duration: |
18 months |
| Compensation: |
None |
| Location: |
UConn Health Center |
| Contact: |
Cheryl Martin, R.N., at 860-679-2943 |
| IRB#: |
05-133 |
[back to top]
|
|
